Green Alpha Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Green Alpha Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$989K	Buy	239,404 +91,860	+62%	+$311K	0.67%	42
2026 Q2	$541K	Sell	147,544 -4,554	-3%	-$15.2K	0.36%	66
2026 Q1	$467K	Buy	152,098 +1,020	+0.7%	+$3.94K	0.46%	61
2025 Q4	$618K	Sell	151,078 -61,124	-29%	-$303K	0.57%	56
2025 Q3	$1.04M	Buy	212,202 +37,109	+21%	+$195K	1%	33
2025 Q2	$886K	Sell	175,093 -3,780	-2%	-$18.6K	0.85%	38
2025 Q1	$946K	Buy	178,873 +111,728	+166%	+$815K	1.01%	28
2024 Q4	$454K	Buy	67,145 +2,346	+4%	+$15.8K	0.36%	95
2024 Q3	$427K	Buy	64,799 +1,800	+3%	+$12.9K	0.34%	96
2024 Q2	$472K	Sell	62,999 -9,435	-13%	-$82.3K	0.38%	93
2024 Q1	$722K	Buy	72,434 +4,563	+7%	+$50.8K	0.52%	75
2023 Q4	$669K	Buy	67,871 +33,329	+96%	+$238K	0.48%	85
2023 Q3	$264K	Buy	+34,542	New	+$345K	0.2%	131

Other funds holding RXRX

CCIA

Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return

WWM

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return

AWM

Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return

WPC

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

TWM

TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

QPBE

Quintet Private Bank (Europe) Luxembourg $2.28B AUM 23.89% 1-Year Est. Return

Green Alpha Advisors's RXRX Position: Q3 2026 in Review

Green Alpha Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 62% in Q3 2026, buying an estimated $311K and bringing the position to 239,404 shares worth $989K. The position accounts for 0.67% of the portfolio, ranked #42.

Green Alpha Advisors first reported a position in RXRX in Q3 2023 and has held it in 13 quarters since. The position peaked at $1.04M in Q3 2025. 20 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Green Alpha Advisors held 239,404 shares of Recursion Pharmaceuticals worth $989K as of Q3 2026.
Green Alpha Advisors bought 91,860 Recursion Pharmaceuticals shares in Q3 2026, an estimated $311K.
Recursion Pharmaceuticals made up 0.67% of Green Alpha Advisors's portfolio in Q3 2026, its #42 holding.
Green Alpha Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 13 quarters since.
Green Alpha Advisors's Recursion Pharmaceuticals position peaked at $1.04M in Q3 2025.
20 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Green Alpha Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.